Skin metastases represent a relatively frequent event in the natural history of melanoma, developing both in early and in late disease stages. Cutaneous or subcutaneous lesions arise in 15-20% of patients; almost 50% of subjects with metastatic disease have soft tissue metastases [1]. The treatment of these lesions is still a challenge: surgical excision and radiotherapy represent the standard treatments for isolated lesions, while melphalan and/or tumour necrosis factor limb perfusion is considered [...]
No takes yet. Share an insight, caveat, or question.
Brizio et al. (2015) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: